1. Introduction {#sec1-antibiotics-09-00231}
===============

Tigecycline is a glycylcycline antibiotic with a broad-spectrum antimicrobial activity against multidrug-resistant organisms (MDROs), such as methicillin-resistant *Staphylococcus aureus*, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, *Acinetobacter baumannii* groups and even those with carbapenem resistance \[[@B1-antibiotics-09-00231],[@B2-antibiotics-09-00231]\]. The activity of tigecycline against MDROs remains stable over time \[[@B3-antibiotics-09-00231]\].

However, the in vitro activity does not always guarantee an adequate clinical response \[[@B4-antibiotics-09-00231]\]. Tigecycline is approved for the treatment of complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia \[[@B5-antibiotics-09-00231]\]. Carbapenems have been recommended as the drug of choice for severe infections caused by ESBL producers. Therefore, clinical data remain limited regarding tigecycline used for the treatment of the infections caused by ESBL-producers \[[@B5-antibiotics-09-00231],[@B6-antibiotics-09-00231]\].

In Taiwan, ESBL production among isolates from cIAI was common \[[@B7-antibiotics-09-00231]\]. The prevalence of ESBL-producing *Escherichia coli* in the community settings has increased from 4.0% to 10.7% from 2002 to 2012 \[[@B8-antibiotics-09-00231]\]. Prior hospitalization, antimicrobial use, and residence in long-term care facilities were presumed associated factors \[[@B8-antibiotics-09-00231],[@B9-antibiotics-09-00231]\]. Moreover, carbapenem has been recognized as one of the main risk factors for the emergence of carbapenem resistance \[[@B10-antibiotics-09-00231],[@B11-antibiotics-09-00231]\]. Other antibiotic agents, such as fluoroquinolones or β-lactam/β-lactamase inhibitors, are promising for the infections caused by ESBL producers \[[@B12-antibiotics-09-00231],[@B13-antibiotics-09-00231]\]. However, these compounds also increasingly contributed to carbapenem resistance among ESBL-producing *Klebsiella pneumoniae* population and correlated with the rise in cefotaxime-resistant *E. coli* in Taiwan \[[@B13-antibiotics-09-00231],[@B14-antibiotics-09-00231],[@B15-antibiotics-09-00231]\].

There are country-wide antimicrobial stewardship programs (ASP) available in Taiwan, implementing strategies and audit of antimicrobial use through hospital inspection and national health insurance payment system \[[@B16-antibiotics-09-00231]\]. ASP systems were beneficial to reduce antibiotic consumption and antimicrobial resistance rate \[[@B17-antibiotics-09-00231],[@B18-antibiotics-09-00231],[@B19-antibiotics-09-00231],[@B20-antibiotics-09-00231],[@B21-antibiotics-09-00231],[@B22-antibiotics-09-00231]\]. However, ESBL prevalence remained substantially high and that would lead to the increased use of carbapenems by ASP recommendations \[[@B23-antibiotics-09-00231],[@B24-antibiotics-09-00231]\]. Therefore, challenges emerge for effective measures in ASP to restrict carbapenem use in ESBL-related infections and thus reduce carbapenem resistance \[[@B25-antibiotics-09-00231],[@B26-antibiotics-09-00231]\].

Tigecycline may be investigated to play a potential role in the alternative strategy to treat ESBL producers \[[@B27-antibiotics-09-00231],[@B28-antibiotics-09-00231]\]. The primary goal of this study was to evaluate the effect of tigecycline-based therapy for patients with infections caused by ESBL-producing *Enterobacteriaceae* in clinical practice in Taiwan. The second goal of the study was to analyze the clinical characteristics predictive of mortality of the patients with these serious infections.

2. Methods {#sec2-antibiotics-09-00231}
==========

2.1. Study Design {#sec2dot1-antibiotics-09-00231}
-----------------

We performed a retrospective, non-comparative, and multicenter cohort study to review the charts of cases infected by ESBL-producing Enterobacteriaceae from 1 January 2015 to 31 October 2016. ESBL phenotype was reported by the local microbiology laboratory of the participated hospitals, according to guidelines by the Clinical and Laboratory Standard Institute \[[@B4-antibiotics-09-00231]\]. The targeted isolates susceptible to carbapenems (including ertapenem, imipenem, and meropenem, designed ESBL-CS) or resistant to carbapenems (including ertapenem, imipenem or meropenem, designed ESBL-CR) were enrolled in the study. However, the isolates with carbapenem resistance testing negative for the ESBL phenotype were not enrolled. During the study period, tigecycline test was not routinely performed for ESBL-producing isolates, but was optional upon a physician request.

2.2. Study Patients {#sec2dot2-antibiotics-09-00231}
-------------------

Patients of age ≥20 years, including immunocompetent and immunocompromised status with cSSTI, cIAI, and/or pneumonia, were analyzed. We enrolled pneumonia of community-acquired and nosocomial infections because ESBL-producers were common etiologies. Although not approved indications, urinary tract infection (UTI) was also enrolled along with secondary bacteremia, if any.

All patients were to have ESBL-producers, which were susceptible to tigecycline and were isolated from cultures of appropriate specimens of wound pus, ascites/intra-abdominal pus, sputum/endobronchial aspirate, and urine samples for cSSTI, cIAI, pneumonia, and UTI respectively. Reports of infectious agents were enforced by laboratory regulations according to the national ASP task force \[[@B16-antibiotics-09-00231]\].

Cases of cSSTI, cIAI, pneumonia, and UTI were defined according to routine clinical practice and previously published clinical trials \[[@B5-antibiotics-09-00231],[@B6-antibiotics-09-00231],[@B27-antibiotics-09-00231],[@B28-antibiotics-09-00231]\]. Patients with multiple infections (two or more diseases of the cSSTI, cIAI, pneumonia, and UTI) were also enrolled.

Patients received an initial dose of 100 mg of tigecycline (Pfizer Pharma GmbH, Berlin, Germany), followed by 50 mg tigecycline every 12 h, either as monotherapy or in combination with other antibiotics (piperacillin-tazobactam, fluoroquinolones, broad-spectrum cephalosporins, or carbapenems), for \>72 h. The cases with concurrent fungemia or bacteremia other than *Enterobacteriaceae* were excluded. Source control and surgical intervention especially for patients with cIAIs or necrotizing cSSTIs were conducted according to routine clinical practice.

2.3. Study Centres {#sec2dot3-antibiotics-09-00231}
------------------

We have retrospectively evaluated the clinical and microbiological responses of patients from 3 medical centers in northern and southern areas of Taiwan. Our investigation was conducted in the three centers, including National Taiwan University Hospital (NTUH, 2200 beds), located in northern Taiwan, that serves an estimated civilian population of 2.6 million mainly from Taipei city, with annual carbapenems, piperacillin/tazobactam and tigecycline consumption rates of about 45, 40, and 3.0 defined daily dose (DDD) per 1000 patient-days respectively \[[@B14-antibiotics-09-00231]\]; Chi-Mei Medical Center (CMMC, leading site, 1278 beds, with annual carbapenems, piperacillin/tazobactam, and tigecycline consumption rates of about 22, 40, and 8.0 DDD/1000 patient-days respectively) and National Cheng Kung University Hospital (NCKU, 1193 beds, with annual carbapenems, piperacillin/tazobactam, and tigecycline consumption rates of about 35, 35, and 2.0 DDD/1000 patient-days respectively). Both CMMC and NCKU are located in southern Taiwan, serving an estimated civilian population of 1.8 million mainly from Tainan city.

2.4. Assessment of Outcomes {#sec2dot4-antibiotics-09-00231}
---------------------------

### 2.4.1. Primary Clinical Outcomes at the End of Therapy (EOT) {#sec2dot4dot1-antibiotics-09-00231}

Cure was defined as the resolution of clinical signs and symptoms of infections compared with baseline, without a requirement for additional antibacterial treatment. Improvement was defined as the partial resolution of clinical signs and symptoms, with a scope of additional antibacterial treatment. Failure was defined as adding or switching to new antibiotics due to poor response, persistence, worsening signs and symptoms, unrelenting signs and symptoms, or persistent isolation of pathogens from the infection sites. Indeterminate was defined as the outcome that could not be assessed for any reason or adding/switching to new antibiotics due to emerging infections (other than initial infection sites) \[[@B5-antibiotics-09-00231],[@B6-antibiotics-09-00231],[@B15-antibiotics-09-00231],[@B27-antibiotics-09-00231]\].

### 2.4.2. Secondary Clinical Outcomes by 30 Days after EOT {#sec2dot4dot2-antibiotics-09-00231}

Mortality referred to overall death and was assessed on the 30th day after the end of therapy (EOT). Clinical success was stringently defined survival without readmission between EOT and the 30th day after EOT. Readmission could be a potential outcome confounder \[[@B28-antibiotics-09-00231],[@B29-antibiotics-09-00231]\].

### 2.4.3. Microbiological Outcomes {#sec2dot4dot3-antibiotics-09-00231}

Follow-up cultures of sampling from primary sites of infections were taken based on routine clinical practice. Eradication was defined as a documented disappearance of baseline infecting pathogens at primary sites of infections from the follow-up cultures. Persistence was defined as documented positive follow-up cultures from primary infection sites. If follow-up cultures were not available, it could be arbitrarily presumed to be eradication based on clinical success (cure or improvement) or to be persistence through clinical failure \[[@B6-antibiotics-09-00231]\]. Superinfection was defined as the emergence of a new isolate at the primary site of infection with worsening signs and symptoms of infection.

### 2.4.4. Data Collection {#sec2dot4dot4-antibiotics-09-00231}

The collected data included demography, comorbidity, dates of admission and onset, source of infection, infection site, symptoms, severity status including the worst physiological variables of the baseline Acute Physiology and Chronic Health Evaluation (APACHE) II score within 48 h of intensive care unit (ICU) admission and real-time Sequential Organ Failure Assessment (SOFA) score during the first 48 h after infection onset, infectious complication, pathogen, empirical antimicrobial therapy, the date of end of therapy, outcome assessment, and the days of hospital stay after the onset of infection. Infections were classified as nosocomial vs. community-acquired depending on the onset of the infection after or before 48 h of hospitalization. Inadequate empirical antibiotic therapy was defined to be greater than 48 h between the time of culture and initiation of treatment using an antimicrobial for which the target pathogen was ultimately determined to be resistant in vitro \[[@B15-antibiotics-09-00231]\].

2.5. Statistical Analyses {#sec2dot5-antibiotics-09-00231}
-------------------------

The baseline characteristics of selected patients from each hospital were analyzed using Pearson's Chi-square test or Fisher's exact test for categorical variables and analysis of variance (ANOVA) or Student's *t*-test for continuous variables. The Kaplan--Meier plot was employed to present the trend on 30-days mortality after infection onset, and the trend differences between the three hospitals were compared using the long-rank test.

The Cox proportional hazard regression analysis through three steps was used to estimate the relative 30-day mortality risk after EOT. Firstly, the above-analyzed significant baseline characteristics, including symptoms, comorbidity, disease severity, and complications, and other potentially confounding variables were further screened by the univariate Cox proportional hazards regression analysis. Secondly, all variables with *p*-values \< 0.05 from the univariate analysis were included in the first multivariable prediction model. Thirdly, the second multivariable prediction model used Collett's model selection approach to find further predictors. This approach used a significance level of 0.10 for the univariate screening, after which the predictors with entry and stay criteria of 0.05 were selected in the final model. All statistical analyses were performed using SAS (version 9.4 for Windows, SAS Institute Inc., Cary, NC, USA). Significance was set at *p*-value \< 0.05 (two-tailed).

2.6. Ethics Approval {#sec2dot6-antibiotics-09-00231}
--------------------

The study was approved by local ethics committees, and was exempted from the requirement for informed consent by the Institutional Review Board (IRB) of the National Taiwan University Hospital (IRB no. 201710028RINB), Taipei; the IRB of Chi Mei Medical Center (IRB no. 10511-002) and the IRB of National Cheng Kung University Hospital (IRB no. A-ER-106-221), Tainan, Taiwan.

3. Results {#sec3-antibiotics-09-00231}
==========

A total of 71 cases that received tigecycline-based therapy for ESBL-producing Enterobacteriaceae with or without carbapenem resistance were enrolled in the study. Among them, 16 were from NTUH, 17 from CMMC, and 38 from NCKU ([Table 1](#antibiotics-09-00231-t001){ref-type="table"}). The infections were predominantly acquired at hospitals (90.1%). CMMC had more community-acquired cases (35.3%, *p* \< 0.0001) and the lowest SOFA score (mean, 6.2, *p* = 0.033). The patients from NTUH had higher rates of post-operation status, source control, carbapenem resistance, septic shock, prolonged prothrombin time, and acute respiratory distress syndrome (ARDS) with statistical significance.

3.1. Patient Characteristics {#sec3dot1-antibiotics-09-00231}
----------------------------

The proportion of female patients in CMMC was significantly lower than others (*p* = 0.04). The patients from NTUH were significantly older in age (mean age, 72.1 years) than those from the other two hospitals (*p* = 0.02). The comorbidities of patients from NTUH involved significantly more respiratory disease, and solid cancer, with a higher Charlson score (mean, 9.5) than other hospitals. Other underlying diseases did not show significant differences among three institutes. No hematological malignancy or other immunocompromised hosts were found in the study. Most patients had multiple comorbidities with a mean Charlson score \>5, most commonly cardiovascular disease (64.8%), metabolic diseases (57.8%), and solid cancer (42.3%). The patients from NTUH had a significantly higher rate of respiratory symptoms (dyspnea and cough) at the onset of infection. Most subjects were critically ill with a mean APACHE II score of more than 20, with 77.5% in the ICUs and 62.0% using mechanical ventilator ([Table 1](#antibiotics-09-00231-t001){ref-type="table"}).

3.2. Infection Sites and Characteristics {#sec3dot2-antibiotics-09-00231}
----------------------------------------

The distribution of infection sites was similar, including cIAI (39.4%), cSSTI (36.6%), pneumonia (32.4%), and rarer in UTI (19.7%). Multiple infection foci were found in 25% of patients. NCKU had significantly fewer cases of pneumonia and UTI, whereas NTUH had a higher proportion of pneumonia and UTI ([Table 1](#antibiotics-09-00231-t001){ref-type="table"}). Carbapenem resistance occurred in about 50% in each infection site (cSSTI, 50%; cIAI, 57%; and pneumonia, 48%). KP (ESBL-CR) was the most common pathogen in patients with cSSTI (46.2%), cIAI (50%), and pneumonia (43.5%; [Table 2](#antibiotics-09-00231-t002){ref-type="table"}).

3.3. Pathogens {#sec3dot3-antibiotics-09-00231}
--------------

The ESBL-producing pathogens included 39 *K. pneumoniae* isolates (28 with carbapenem resistance), 30 *E. coli* isolates (3 with carbapenem resistance), 4 *Enterobacter cloacae* isolates (2 with carbapenem resistance), and 1 *Citrobacter freundii*. Four patients had concurrent *E. coli* and *K. pneumoniae* infection.

Nearly all patients received combination therapy, mostly with carbapenems (meropenem, imipenem, or doripenem), followed by cefepime, ceftazidime, piperacillin-tazobactam, cefpirome, piperacillin, and rarely, ciprofloxacin or levofloxacin. The rate of inappropriate empirical antimicrobial therapy was highly distributed among three hospitals without any significant difference (mean, 84.5%, [Table 1](#antibiotics-09-00231-t001){ref-type="table"}). The remarkably high rate of inadequate empirical antibiotic therapy in three centers was due to a high proportion of carbapenem resistance and the unexpected presence of ESBL.

The outcome revealed that the patients from NTUH had significantly lower rates of clinical success (43.8%) and microbiological eradication (0%) at EOT, accompanied by the lowest survival rate by 30 days after EOT (37.5%). However, survival duration analysis for the 30-day mortality of the population among the three centers using the Kaplan--Meier technique showed no noteworthy difference between each of the paired comparisons ([Figure 1](#antibiotics-09-00231-f001){ref-type="fig"}).

Overall, the rates of clinical success and microbiological eradication at EOT were 63.4% and 50.7%, respectively. The overall mortality by 30 days after EOT was 36.6%. The mean length of stay at the hospital after the infection was 44.7 days, which was not significantly variable in any of the three hospitals ([Table 1](#antibiotics-09-00231-t001){ref-type="table"}).

During the study period, the tigecycline susceptibility test was optional upon a physician request. We only can enroll tigecycline-susceptible cases (probably the physician would use tigecycline based on susceptibility), but persistent isolates at the end of therapy usually lacked tigecycline susceptibility (probably the physician switched to other drugs and did not request tigecycline testing). We could not say the development of tigecycline resistance explaining the cases with failure of microbiological eradication. From very limited cases with persistent isolates doing tigecycline susceptibility testing, tigecycline remained susceptible at the end of therapy.

The clinical outcomes of tigecycline-based treatment per patient subgroup by infection sites are shown in [Table 2](#antibiotics-09-00231-t002){ref-type="table"}. The cSSTI, cIAI, and pneumonia were successfully treated in 61.5%, 60.7%, and 52.2% patients at EOT respectively. We did not evaluate the detailed outcomes of the UTI, because tigecycline was not primarily used to treat UTI, and 11 of 14 UTIs (78.6%) were accompanied infections with either cSSTI, cIAI, and/or pneumonia. The UTI and multiple infections were successfully treated in 57.1% and 44.4% patients at EOT respectively.

For cSSTI, the clinical and microbiological outcomes at EOT and survival 30 days post EOT, the ESBL-CS group had apparently higher clinical success rates (about 60--70%) than ESBL-CR group (about 20--50%), which were statistically insignificant. Meanwhile, the *E*. *coli* group had a better clinical success than the *K. pneumoniae* group at EOT (90% vs. 50%, *p* = 0.08) and by 30 days after EOT (90% vs. 36%, *p* = 0.01).

For cIAI, the clinical and microbiological outcomes at EOT and 30 days after EOT, either by *E. coli* or *K. pneumoniae* (ESBL-CS or ESBL-CR), were about 40--60% successful, holding no significance.

For pneumonia, the ESBL-CS group had higher clinical success rates than ESBL-CR at EOT (69.2% vs. 36.4%) and by 30 days after EOT (50.8% vs. 27.3%), although not statistically significant. The *E. coli* group showed a significantly higher clinical success rate than *K. pneumoniae* group at EOT (80% vs. 36%, *p* = 0.047). The microbiological outcomes of pneumonia revealed significant success in eradicating all ESBL-CS strains compared to all ESBL-CR ones (69.2% vs. 0%, *p* = 0.0006), especially in *K. pneumoniae* (ESBL-CS) versus *K. pneumoniae* (ESBL-CR) groups (75% vs. 0%, *p* = 0.011).

3.4. Risk Factors for Poor Clinical Outcome {#sec3dot4-antibiotics-09-00231}
-------------------------------------------

The characteristic of the subjects with clinical success (survival without readmission) or mortality by 30 days after EOT was evaluated using univariate analysis ([Table 3](#antibiotics-09-00231-t003){ref-type="table"}). The statistically significant predictors for mortality were found to be dyspnea, severity status (stay in ICU, ventilator use and SOFA score), and infectious complications (septic shock, acute renal failure, thrombocytopenia, prolonged prothrombin time, and neurologic complications). The clinical and microbiological outcomes at EOT were also correlated with clinical success by 30 days after EOT using both models (*p* \< 0.0001). The mean length of stay after the infection was longer in the survival group than that in the mortality group (52.1 vs. 32.9, *p* = 0.03). The above-mentioned significant patient characteristics, microbiological eradication and other potential confounders, such as hospitals, Charlson score, carbapenem resistance, antibiotic therapy, and source control were further forwarded to the Cox proportional hazards regression analysis.

3.5. Hazard Ratio for Outcome {#sec3dot5-antibiotics-09-00231}
-----------------------------

[Table 4](#antibiotics-09-00231-t004){ref-type="table"} shows independent factors associating with mortality by using Cox proportional hazards regression model. Univariate analysis revealed that dyspnea (*p* = 0.003), SOFA score (*p* = 0.0004), SOFA score \>8 (*p* = 0.001), septic shock (*p* = 0.022), thrombocytopenia (*p* = 0.0004), prolonged prothrombin time (*p* = 0.018), and lack of microbiological eradication ability (*p* = 0.004) were considerably associated with mortality by 30 days after EOT.

Cox regression proportional hazard model revealed that only dyspnea (*p* = 0.008--0.009) and SOFA score \> 8 (*p* = 0.041) were associated with the time to death. The prolonged prothrombin time and lack of microbiological eradication were found to be inconsistently associated with mortality when different approaching models were used. The Collett's model selection approach revealed that only dyspnea (*p* = 0.0002) and SOFA \> 8 score (*p* = 0.004) significantly predicted mortality, with nearly 7.3-fold and 4.6-fold increased odds of dying respectively. Therefore, no specific factors of carbapenem resistance, empirical antimicrobial therapy, source control, ventilator use, ICU stay, or hospitals were associated with time to mortality ([Table 4](#antibiotics-09-00231-t004){ref-type="table"}), even though NTUH had a relatively higher number of cases with source control ([Table 1](#antibiotics-09-00231-t001){ref-type="table"}).

4. Discussion {#sec4-antibiotics-09-00231}
=============

Our multicenter study focused on the tigecycline effectiveness versus infections caused by ESBL-producing *Enterobacteriaceae* susceptible or resistant towards carbapenems, in an almost evenly distributed infection sites of cIAI (39.4%), cSSTI (36.6%), and pneumonia (32.4%). The clinical success and microbiological eradication rates at EOT of tigecycline-based therapy were 63.4% and 50.7% respectively. The mean clinical success rate was 57.8% by 30 days after EOT, including cSSTI (57.7%), cIAI (57.1%), and pneumonia (43.5%).

In our study, *K. pneumoniae* (ESBL-CR) was the most common isolate (39.4% of the patients), followed by *E. coli* (ESBL-CS, 38.0%), *K. pneumoniae* (ESBL-CS, 15.5%), and *E. coli* (ESBL-CR, 4.2%). The *E. coli-*infected group (regardless of carbapenem resistance) had an overall higher clinical success or survival rate than *K. pneumoniae-*infected group. A large study of patients with bacteremia in 12 countries reported ESBL-producing *K. pneumoniae* contributed significantly more mortality rate than the ESBL-producing *E. coli* (34% vs. 17%) \[[@B30-antibiotics-09-00231]\]. In similar, *E. coli* has a better survival rate than *Klebsiella* species (75% vs. 23%) in adults with community-onset bacteremia \[[@B23-antibiotics-09-00231]\].

The effect of tigecycline-based therapy was lower than a previous report demonstrating a high overall clinical success rate (91.0%, 61/67) for ESBL-related infections \[[@B5-antibiotics-09-00231]\]. The difference in the clinical success rate between our study and the previous report was statistically significant (63.4% vs. 91.0%, *p* = 0.0001). In another large series of cIAI patients, treatment was successful in 426 (70.3%) of 606 tigecycline-treated patients \[[@B28-antibiotics-09-00231]\]. The difficulty of our study in attaining a high success rate could perhaps be justified by the data of *K. pneumoniae* (ESBL-CR) and a high proportion (80.5%) with inappropriate empirical antimicrobial therapy.

Carbapenem resistance is more common among infections caused by the Enterobacteriaceae and was associated with a significantly higher risk of mortality in comparison to carbapenem-susceptible Enterobacteriaceae \[[@B31-antibiotics-09-00231]\].

In our previous study, we demonstrated that tigecycline activity was unaffected by ESBL production and had an MIC~90~ ranging from 0.5 to 1.5 μg/mL for ESBL-producing *K. pneumoniae*, *Serratia marcescens,* and *E. cloacae* \[[@B32-antibiotics-09-00231]\]. In a total of 2870 blood samples in India, all ESBL producers were sensitive to tigecycline \[[@B33-antibiotics-09-00231]\]. In a small collection of serious infections by *K. pneumoniae*, the cure rate for tigecycline in patients with multidrug-resistant *K. pneumoniae* was 5/6 (83.3%). All six patients achieved microbiological eradication \[[@B6-antibiotics-09-00231]\]. Nonetheless, due to the high frequency of carbapenem resistance in infections of ESBL-producing *Enterobacteriaceae*, the treatment of choice for these ESBL-related infections should not always consider a carbapenem as an empirical regimen. The tigecycline-based therapy should be efficiently developed ahead to treat these infections empirically rather than just reserving it as a specific therapy at a later stage.

Bloodstream infections caused by ESBL-producing *Enterobacteriaceae* have been associated with higher mortality than those by non-ESBL producers \[[@B23-antibiotics-09-00231],[@B34-antibiotics-09-00231]\]. This was also seen in our patients having pneumonia or cSSTI. The success rates seemed to be lower in patients with pneumonia caused by *K. pneumoniae* (50% of ESBL-CS and 30% of ESBL-CR groups), due to difficulty in the microbiological eradication of *K. pneumoniae* (ESBL-CR) in cases of pneumonia (0/10). Our results add evidence that tigecycline is not recommended to treat pneumonia by *K. pneumoniae* (ESBL-CR) strains.

A higher concentration of tigecycline or combination of tigecycline with colistin rendering good in vitro synergistic activity against ESBL-producing *K. pneumoniae* or with carbapenem resistance could be further reassessed for clinical success \[[@B35-antibiotics-09-00231],[@B36-antibiotics-09-00231],[@B37-antibiotics-09-00231]\]. The combination of tigecycline with colistin, aminoglycoside or doxycycline might be active against the ESBL-CR infections in several studies in Taiwan \[[@B37-antibiotics-09-00231],[@B38-antibiotics-09-00231],[@B39-antibiotics-09-00231]\].

Most of our patients (78%) were critically ill and stayed in the ICUs. Although the univariate analysis revealed several risk factors for mortality, including dyspnea, SOFA score \> 8, septic shock, thrombocytopenia, prolonged prothrombin time, and inability towards microbiological eradication, the Cox regression proportional model demonstrated that only dyspnea and SOFA score or SOFA \> 8 were independently associated with the estimated time towards death. The SOFA score has been a useful predictor of clinical outcome and an initial score of 8--11 was associated with a 60% ICU mortality \[[@B40-antibiotics-09-00231]\]. About 82% of the patients with dyspnea used the respiratory ventilator. A further study may be required to investigate the relationship of outcome and various ventilator modes. Our study proposes that late-onset mortality could be predicted by the useful warning sign of dyspnea and a SOFA score, which represents real-time disease severity during the infection onset.

5. Conclusions {#sec5-antibiotics-09-00231}
==============

The limitations of this study included retrospective observational design, a lack of information about tigecycline side effects and drug interactions, a lack of information about development of tigecycline resistance, and the low number and its heterogeneity in demographics. However, the infection sites of cohort were almost evenly distributed. The clinical experience of tigecycline in the ESBL-related infections was limited in current practice. This multicenter study enrolling a sizeable sample of patients provides an evident basis of future generalization in the design of tigecycline-based strategies against the critically ill infections by ESBL producers. The tigecycline-based therapy for ESBL-producers was highly active (80--90% success rates) against pneumonia and cSSTI by *E. coli*, but showed moderate response (50--60% success rates) for cIAI caused by *E. coli* or *K. pneumoniae*. Microbiological eradication of *K. pneumoniae* with carbapenem resistance was difficult to achieve in pneumonia, for which tigecycline-based therapy should not be recommended. The relative effects of tigecycline might be cautiously integrated into ASP recommendation as an alternative regimen in future. Some variables could be useful to predict outcomes of critically ill patients. High SOFA score and dyspnea were independently associated with time till death even when the patients were put on ventilator.
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###### 

Demographic data, comorbidity, symptoms, infectious status, pathogens, and outcome of the patients who received tigecycline-based therapy for ESBL-producing *Enterobacteriaceae* with or without carbapenem resistance in 3 medical centers in Taiwan.

  Variables                                       NTUH (*n* = 16)   CMMC (*n* = 17)   NCKU (*n* = 38)   *p*      Total (*n* = 71)
  ----------------------------------------------- ----------------- ----------------- ----------------- -------- ------------------
  Sex, no (%)                                                                                                    
  Female                                          5 (31.3)          3 (17.7)          20 (52.6)         0.04     28 (39.4)
  Male                                            11 (68.8)         14 (82.4)         18 (47.4)                  
  Age (mean ± SD)                                 72.1 ± 15.4       66.3 ± 19.7       59.9 ± 13.8       0.02     64.2 ± 16.3
  Underlying diseases, no (%)                                                                                    
  Cardiovascular disease                          10 (62.5)         12 (70.6)         24 (63.2)         0.894    46 (64.8)
  Respiratory disease                             10 (62.5)         5 (29.4)          1 (2.7)           \<0001   16 (22.5)
  Neurological disease                            6 (37.5)          5 (29.4)          5 (13.2)          0.09     16 (22.5)
  Hepatobiliary disease                           6 (37.5)          7 (41.2)          10 (26.3)         0.50     23 (32.4)
  Metabolic disease                               11 (68.8)         7 (41.2)          23 (60.5)         0.27     41 (57.8)
  Autoimmune disease                              2 (12.5)          0 (0.0)           1 (2.6)           0.18     3 (4.2)
  Solid cancer                                    9 (56.3)          2 (11.8)          19 (50.0)         0.01     30 (42.3)
  Charlson score (mean ± SD)                      9.5 ± 3.5         2.8 ± 2.0         4.3 ± 2.2         \<0001   5.1 ± 3.5
  Community-acquired, no (%)                      1 (6.3)           6 (35.3)          0 (0.0)           \<0001   7 (9.9)
  Symptoms on onset, no (%)                                                                                      
  Fever                                           7 (43.8)          11 (64.7)         14 (36.8)         0.16     32 (45.1)
  Chest pain                                      0 (0.0)           1 (5.9)           1 (2.6)           0.72     2 (2.8)
  Diarrhea                                        4 (25.0)          2 (11.8)          2 (5.3)           0.07     8 (11.3)
  Dyspnea                                         13 (81.3)         7 (41.2)          2 (5.3)           \<0001   22 (31.0)
  Cough                                           6 (37.5)          2 (11.8)          0 (0.0)           0.0003   8 (11.3)
  Infection site, no (%)                                                                                         
  cSSTI                                           9 (56.3)          3 (17.7)          14 (36.8)         0.08     26 (36.6)
  cIAI                                            6 (37.5)          4 (23.5)          18 (47.4)         0.23     28 (39.4)
  Pneumonia                                       10 (62.5)         10 (58.8)         3 (7. 9)          \<0001   23 (32.4)
  UTI                                             8 (50.0)          3 (17.6)          3 (7.9)           0.002    14 (19.7)
  Severity status, no (%)                                                                                        
  Secondary bacteremia                            5 (31.3)          2 (11.8)          3 (7.9)           0.07     10 (14.1)
  Stay in ICU                                     12 (75.0)         14 (82.4)         29 (76.3)         0.87     55 (77.5)
  Post operation status                           9 (56.3)          8 (47.1)          2 (5.3)           \<0001   19 (26.8)
  Ventilator use                                  12 (75.0)         13 (76.5)         19 (50.0)         0.10     44 (62.0)
  SOFA score (mean ± SD)                          7.8 ± 2.8         6.2 ± 5.1         9.3 ± 4.2         0.03     8.2 ± 4.3
  APACHE II score (mean ± SD)                     20.3 ± 9.9        23.5 ± 9.9        \- ^a^            0.46     \- ^a^
  Complications, no (%)                                                                                          
  Septic shock                                    13 (81.3)         7 (41.2)          18 (47.4)         0.04     38 (53.5)
  Acute renal failure                             10 (62.5)         7 (41.2)          18 (47.4)         0.46     35 (49.3)
  Liver function impairment                       4 (25.0)          6 (35.3)          25 (65.8)         0.01     35 (49.3)
  Platelet count \<100,000/μL                     6 (37.5)          5 (29.4)          15 (39.5)         0.80     26 (36.6)
  Prolonged prothrombin time                      8 (50.0)          3 (17.7)          2 (5.3)           0.0006   13 (18.3)
  ARDS                                            10 (62.5)         0 (0.0)           0 (0.0)           \<0001   10 (14.1)
  Neurological complication                       3 (18.8)          0 (0.0)           13 (34.2)         0.009    16 (22.5)
  Pathogen, no (%)                                                                                               
  *Escherichia coli*                              2                 14                14                         30
  With carbapenem resistance                      2 (100.0)         0 (0.0)           1 (7.1)           0.007    3 (10.0)
  *Klebsiella pneumoniae*                         14                3                 22                         39
  With carbapenem resistance                      14 (100.0)        0 (0.0)           14 (63.6)         \<0001   28 (71.8)
  Empirical Antibiotic therapy                                                                                   
  Inappropriate                                   16 (100.0)        13 (76.5)         31 (81.6)         0.1      60 (84.5)
  Therapy for infection, no (%)                                                                                  
  Antibiotic only                                 5 (31.3)          12 (70.6)         31 (81.6)         0.001    48 (67.6)
  Antibiotic + source control                     11 (68.8)         5 (29.4)          7 (18.4)                   23 (32.4)
  Clinical outcome on EOT                                                                                        
  Success (cure/improvement)                      7 (43.8)          14 (82.4)         24 (63.2)         0.02     45 (63.4)
  Failure                                         6 (37.5)          3 (17.7)          14 (36.8)                  23 (32.4)
  Undetermined                                    3 (18.8)          0 (0.0)           0 (0.0)                    3 (4.2)
  Microbiological outcome on EOT                                                                                 
  Eradication                                     0 (0.0)           12 (70.6)         24 (63.2)         \<0001   36 (50.7)
  Clinical outcome on 30 days after EOT ^b^                                                                      
  Success (survival, no readmission)              6 (37.5)          12 (75.0)         23 (60.5)         0.04     41 (57.8)
  Overall death                                   8 (50.0)          3 (18.8)          15 (39.5)                  26 (36.6)
  Readmission                                     2 (12.5)          1 (6.3)           0 (0.0)                    3 (4.2)
  Days on discharge after infection (mean ± SD)   44.7 ± 39.7       35.7 ± 25.6       48.7 ± 46.9       0.86     44.7 ± 40.9

Note: cSSTI, complicated skin and skin tissue infections; cIAI, complicated intra-abdominal infections; UTI, urinary tract infection; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; ^a^ Data were incomplete in National Cheng Kung University Hospital (NCKU); EOT, end of therapy; ^b^ One patient data was indeterminate in Chi-Mei Medical Center (CMMC).
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###### 

EOT outcome and success (survival without readmission) by 30 days after EOT for patients with cSSTI, cIAI or pneumonia stratified by pathogens.

  Bacteriology                         Success at EOT (Cure/Improvement)   *p*    Microbiological Eradication at EOT   *p*      Success by 30 Days after EOT   *p*
  ------------------------------------ ----------------------------------- ------ ------------------------------------ -------- ------------------------------ ------
  cSSTI (*n* = 26) ^a^                 16 (61.5%)                                 11 (42.3%)                                    15 (57.7%)                     
  ESBL-CS (*n* = 13)                   9 (69.2%)                           0.69   8 (61.5%)                            0.11     10 (76.9%)                     0.11
  ESBL-CR (*n* = 13)                   7 (53.8%)                                  3 (23.1%)                                     5 (38.5%)                      
  *Escherichia coli* (*n* = 10)        9 (90%)                                    7 (70%)                                       9 (90%) ^b^                    
  ESBL-CS (*n* = 9)                    8 (88.9%)                                  7 (77.8%)                                     8 (88.9%)                      
  ESBL-CR (*n* = 1)                    1 (100%)                                   0 (0%)                                        1 (100%)                       
  *Klebsiella pneumoniae* (*n* = 14)   7 (50%)                                    4 (28.6%)                                     5 (35.7%) ^b^                  
  ESBL-CS (*n* = 2)                    1 (50%)                                    1 (50%)                                       1 (50%)                        
  ESBL-CR (*n* = 12)                   6 (50%)                                    3 (25%)                                       4 (33.3%)                      
  cIAI (*n* = 28) ^c^                  17 (60.7%)                                 13 (46.4%)                                    16 (57.1%)                     
  ESBL-CS (*n* = 13)                   7 (53.8%)                           0.22   6 (46.2%)                            0.90     6 (46.2%)                      0.38
  ESBL-CR (*n* = 16)                   10 (62.5%)                                 7 43.8%)                                      10 (62.5%)                     
  *Escherichia coli* (*n* = 10)        7 (60%)                                    5 (50%)                                       6 (60%)                        
  ESBL-CS (*n* = 8)                    5 (62.5%)                                  4 (50%)                                       4 (50%)                        
  ESBL-CR (*n* = 2)                    2 (100%)                                   1 (50%)                                       2 (100%)                       
  *Klebsiella pneumoniae* (*n* = 19)   9 (47.4%)                                  7 (36.8%)                                     9 (47.4%)                      
  ESBL-CS (*n* = 5)                    2 (40%)                                    2 (40%)                                       2 (40%)                        
  ESBL-CR (*n* = 14)                   7 (50%)                                    5 (35.7%)                                     7 (50%)                        
  Pneumonia (*n* = 23) ^d^             12 (52.2%)                                 9 (39.1%)                                     10 (43.5%)                     
  ESBL-CS (*n* = 13)                   9 (69.2%)                           0.22   9 (69.2%)                            0.0006   7 (53.8%)                      0.24
  ESBL-CR (*n* = 11)                   4 (36.4%)                                  0 (0%)                                        3 (27.3%)                      
  *Escherichia coli* (*n* = 10)        8 (80%) ^e^                                6 (60%)                                       6 (60%)                        
  ESBL-CS (*n* = 9)                    7 (77.8%)                                  6 (66.7%)                            0.40     5 (55.6%)                      
  ESBL-CR (*n* = 1)                    1 (100%)                                   0 (0%)                                        1 (100%)                       
  *Klebsiella pneumoniae* (*n* = 14)   5 (35.7%) ^e^                              3 (21.4%)                                     4 (28.6%)                      
  ESBL-CS (*n* = 4)                    2 (50%)                                    3 (75%)                              0.011    2 (50%)                        
  ESBL-CR (*n* = 10)                   3 (30%)                                    0 (0%)                                        2 (20%)                        
  Multiple infections (*n* = 18)       8 (44.4%)                                  4 (22.2%)                                     6 (33.3%)                      

Note. EOT, end of therapy; cSSTI, complicated skin and skin tissue infections; ESBL-CS, ESBL with carbapenem susceptibility; ESBL-CR, ESBL with carbapenem resistance; ^a^ Two cases were infected *Enterobacter cloacae*; ^b^ 90% vs. 35.7%, *p* = 0.01; cIAI, complicated intra-abdominal infection; ^c^ Three cases had both *E. coli* and *K. pneumoniae* and two cases were infected *E. cloacae*; ^d^ One case was infected by both *Escherichia coli* and *Klebsiella pneumoniae*; ^e^ 80% vs. 35.7%, *p* = 0.047.
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###### 

Predictors for the clinical outcome by 30 days after the end of therapy (EOT) ^a.^

  Variables, no. (%)                              Success (Survival without Readmission) (*n* = 41)   All-Cause Death (*n* = 26)   *p*
  ----------------------------------------------- --------------------------------------------------- ---------------------------- ----------
  Sex, no (%)                                                                                                                      
  Female                                          13 (31.7)                                           14 (53.8)                    0.08
  Male                                            28 (68.3)                                           12 (46.2)                    
  Age                                             63.1 ± 16.4                                         64.7 ± 16.6                  0.93
  Acquired source of infection                                                                                                     
  Community                                       5 (12.2)                                            1 (3.9)                      0.15
  Hospital and healthcare institute               36 (87.8)                                           25(96.2)                     
  Symptoms on onset                                                                                                                
  Fever                                           21 (51.2)                                           8 (30.8)                     0.13
  Dyspnea                                         7 (17.1)                                            12 (46.2)                    0.01
  Cough                                           3 (7.3)                                             5 (19.2)                     0.25
  Chest pain                                      2 (4.9)                                             0 (0.0)                      0.52
  Diarrhea                                        5 (12.2)                                            2 (7.7)                      0.70
  Infection site                                                                                                                   
  cSSTI                                           15 (36.6)                                           9 (34.6)                     \>999
  cIAI                                            16 (39.0)                                           12 (46.2)                    0.62
  Pneumonia                                       10 (24.4)                                           10 (38.5)                    0.28
  UTI                                             5 (12.2)                                            6 (23.1)                     0.32
  Severity status                                                                                                                  
  Secondary bacteremia                            6 (14.6)                                            4 (15.4)                     \>999
  Stay in ICU                                     28 (68.3)                                           24 (92.3)                    0.03
  Post operation status                           12 (29.3)                                           4 (15.4)                     0.25
  Ventilator use                                  21 (51.2)                                           20 (76.9)                    0.04
  SOFA score                                      6.71 ± 3.7                                          10.77 ± 4.3                  0.0004
  APACHE II score                                 21.4 ± 10.0                                         20.0 ± 8.8                   0.77 ^b^
  Underlying diseases                                                                                                              
  Cardiovascular disease                          28 (68.3)                                           16 (61.5)                    0.61
  Respiratory disease                             9 (22.5)                                            6 (23.1)                     \>999
  Neurological disease                            8 (19.5)                                            5 (19.2)                     \>999
  Hepatobiliary disease                           16 (39.0)                                           6 (23.1)                     0.20
  Metabolic disease                               27 (65.9)                                           12 (46.2)                    0.13
  Autoimmune disease                              1 (2.4)                                             2 (7.7)                      0.56
  Solid cancer                                    17 (41.5)                                           11 (42.3)                    \>999
  Charlson score (mean ± SD)                      4.6 ± 2.8                                           5.6 ± 4.1                    0.68
  Complications                                                                                                                    
  Septic shock                                    18 (43.9)                                           19 (73.1)                    0.03
  Acute renal failure                             16 (39.0)                                           17 (65.4)                    0.047
  Liver function impairment                       19 (46.3)                                           16 (61.5)                    0.32
  Platelet count \< 100,000/μL                    8 (19.5)                                            17 (65.4)                    0.0002
  Prolonged prothrombin time                      4 (9.8)                                             8 (30.8)                     0.048
  ARDS                                            4 (9.8)                                             5 (19.2)                     0.29
  Neurological complication                       6 (14.6)                                            10 (38.5)                    0.04
  Pathogen, no (%)                                                                                                                 
  *Escherichia coli* (ESBL-CR)                    3 (14.3)                                            0 (0.0)                      0.55
  *Klebsiella pneumoniae* (ESBL-CR)               12 (66.7)                                           14 (73.7)                    0.73
  Therapy for infection, no (%)                                                                                                    
  Appropriate empirical antibiotic therapy        6 (14.6)                                            5 (19.2)                     0.74
  Antibiotic + source control                     15 (36,6)                                           6 (23.1)                     0.25
  Clinical outcome on EOT                                                                                                          
  Success (cure/improvement)                      38 (92.7)                                           3 (11.5)                     \<0001
  Failure                                         3 (7.32)                                            20 (76.92)                   
  Undetermined                                    0 (0.00)                                            3 (11.54)                    
  Microbiological outcome on EOT                                                                                                   
  Eradication                                     29 (70.7)                                           5 (19.2)                     \<0001
  Days on discharge after infection (mean ± SD)   52.1 ± 46.79                                        32.9 ± 29.3                  0.03

Note. ARDS, acute respiratory distress syndrome; ESBL-CR, ESBL with carbapenem resistance; EOT, end of therapy; ^a^ excluded one patient of indeterminate in CMMC and 3 patients with readmission; ^b^ Data were incomplete in NCKU.
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###### 

Hazard ratio of 30 days mortality after end of therapy using the Cox regression model.

  Variables                       Heading              Heading   Model 1 (*p* \< 0.05 with Categorical)   Model 2 (Collett's Model Selection Approach)                        
  ------------------------------- -------------------- --------- ---------------------------------------- ---------------------------------------------- -------------------- --------
  Hospital                                                                                                                                                                    
  NTUH                            reference                                                                                                                                   
  CMMC                            0.31 (0.06--1.53)    0.150                                                                                                                  
  NCKU                            0.53 (0.19--1.53)    0.243                                                                                                                  
  Dyspnea symptom                 4.71 (1.71--13.00)   0.003     14.49 (2.01--104.48)                     0.008                                          7.33 (2.58--20.78)   0.0002
  Stay in ICU                     2.27 (0.52--10.00)   0.278                                                                                                                  
  Ventilator use                  2.17 (0.70--6.73)    0.180                                                                                                                  
  SOFA score                      1.22 (1.09--1.36)    0.0004                                                                                                                 
  SOFA score (categorical)                                                                                                                                                    
  ≤8                              reference                      reference                                                                               reference            
  \>8                             7.95 (2.26--27.96)   0.001     10.04 (1.10--92.00)                      0.041                                          4.58 (1.64--12.79)   0.004
  APACHE II score                 1.01 (0.94--1.08)    0.812                                                                                                                  
  APACHE II score (categorical)                                                                                                                                               
  ≤20                             reference                                                                                                                                   
  \>20                            1.32 (0.46--3.79)    0.612                                                                                                                  
  Charlson score                  1.09 (0.96--1.24)    0.187                                                                                                                  
  Charlson (categorical)                                                                                                                                                      
  0                               reference                                                                                                                                   
  1                               0.88 (0.06--14.10)   0.929                                                                                                                  
  ≥2                              0.78 (0.10--5.97)    0.815                                                                                                                  
  Complications                                                                                                                                                               
  Septic shock                    4.35 (1.24--15.29)   0.022     1.68 (0.23--12.38)                       0.612                                                               
  Acute renal failure             2.52 (0.87--7.25)    0.088                                                                                                                  
  Thrombocytopenia                9.70 (2.75--34.15)   0.0004    0.47 (0.04--5.82)                        0.558                                                               
  Prolonged prothrombin time      3.39 (1.23--9.35)    0.018     0.28 (0.04--2.06)                        0.210                                                               
  ARDS                            2.21 (0.71--6.85)    0.170                                                                                                                  
  Neurological complication       1.69 (0.59--4.87)    0.331                                                                                                                  
  Microbiological eradication     0.11 (0.03--0.50)    0.004     0.16 (0.03--0.93)                        0.042                                                               
  *Klebsiella pneumoniae*                                                                                                                                                     
  ESBL-CS                         reference                                                                                                                                   
  ESBL-CR                         0.71 (0.21--2.35)    0.574                                                                                                                  
  Therapy for infections                                                                                                                                                      
  Antibiotic only                 reference                                                                                                                                   
  Antibiotic + source control     0.43 (0.10--1.91)    0.269                                                                                                                  
  Empirical antibiotic therapy                                                                                                                                                
  Appropriate                     reference                                                                                                                                   
  Inappropriate                   0.52 (0.17--1.61)    0.255                                                                                                                  

Note. ICU, intensive care unit; ARDS, acute respiratory distress syndrome; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation; ESBL-CS: ESBL with carbapenem susceptibility; ESBL-CR: ESBL with carbapenem resistance.
